Sign in
Taking peopleNo phase

False Lumen Treatment for Prevention of Aortic Growth Using Shape Memory Polymer - First-in-Human Study

Key facts

Who runs it
Shape Memory Medical, Inc.
Where
New Zealand2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
30 people, planned
Started
24 Feb 2026
Expected to end
15 Feb 2029
Type of study
Interventional
Treatments tested
  • False Lumen Embolization System, IMPEDE-FX RapidFill
Record updated
23 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • ≥18 years of age
  • A candidate for false lumen (FL) embolization with a type B dissection, and no prior primary entry tear/TL treatment, OR
  • A candidate for FL embolization with a type B or type A dissection, in whom the primary entry tear/TL was treated in a previous procedure, and is now presenting with a FL requiring treatment

Who cannot take part

  • Untreated or uncovered primary entry/reentry tear proximal to left subclavian artery (before FL treatment with the investigational product)
  • Vascular disease, aortic rupture, and/or anatomy and/or dissection membrane condition that precludes the safe access and positioning of an introducer sheath and delivery (and expansion) of the investigational product into the FL
  • Prior treatment of the FL
  • Planned use of investigational devices to treat the primary entry tear and/or TL
  • Planned use of FL embolic devices other than the investigational product
  • Prior abdominal aortic aneurysm (AAA) treatment
  • Planned concomitant major surgery (e.g., gastrointestinal surgery)
  • Cerebrovascular accident within 90 days prior to the procedure
  • Myocardial infarction and/or major heart surgery within 90 days prior to the procedure
  • Participant is planning to become pregnant or is currently pregnant or lactating. For participants of child-bearing potential, based on a positive pregnancy test within 7 days prior to the procedure or refusal to use a medically accepted method of birth control for the duration of the study
  • Diagnosed or suspected congenital degenerative connective tissue disease (e.g., Marfan's or Ehler-Danlos syndrome)
  • Coagulopathy or uncontrolled bleeding disorder
  • Known hypersensitivity or contraindication to platinum, iridium, or polyurethane
  • A condition that inhibits radiographic visualization during the study procedure and planned follow-up imaging
  • History of allergy to contrast medium that cannot be managed medically
  • Uncontrolled comorbid medical condition, including mental health issues, that, in the opinion of the investigator, would adversely affect participation in the study
  • Serum creatinine level >220 µmol/L (within 90 days prior to the procedure)
  • Life expectancy of <2 years postprocedure
  • An inability to provide informed consent
  • Enrolled in another clinical study other than a registry
  • Hyperacute or acute aortic dissection (<15 days from symptom onset)
  • Absence of/inability to create a reentry tear/fenestration adequately positioned and large enough to allow introducer sheath access into the FL
  • Atrial fibrillation that is not well rate controlled
  • Unable or unwilling to comply with study follow-up requirements

This trial is currently available in New Zealand.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To determine the safety and feasibility of the investigational product to reduce aortic dissection false lumen perfusion.

The group in the trial

  • Experimental: InterventionTreatment being tested

    Device: False Lumen Embolization System Device: IMPEDE-FX RapidFill

    Treatment: False Lumen Embolization System, IMPEDE-FX RapidFill

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
23 March 2026